241 related articles for article (PubMed ID: 28345268)
1. Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement.
Iorio A; Iserman E; Blanchette V; Dolan G; Escuriola Ettingshausen C; Hermans C; Negrier C; Oldenburg J; Reininger A; Rodriguez-Merchan C; Spannagl M; Valentino LA; Young G; Steinitz-Trost KN; Gringeri A
Haemophilia; 2017 May; 23(3):e170-e179. PubMed ID: 28345268
[TBL] [Abstract][Full Text] [Related]
2. Individualizing factor replacement therapy in severe hemophilia.
Carcao MD; Iorio A
Semin Thromb Hemost; 2015 Nov; 41(8):864-71. PubMed ID: 26270111
[TBL] [Abstract][Full Text] [Related]
3. Rationale for individualizing haemophilia care.
Sørensen B; Auerswald G; Benson G; Elezović I; Felder M; Lambert T; Morfini M; Remor E; Salaj P; Santagostino E; Šalek SZ; Ljung R
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):849-57. PubMed ID: 25396764
[TBL] [Abstract][Full Text] [Related]
4. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
Ahnström J; Berntorp E; Lindvall K; Björkman S
Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
[TBL] [Abstract][Full Text] [Related]
5. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
Dodd C; Watts RG
Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement.
Tiede A; Giangrande P; Teitel J; Amano K; Benson G; Nemes L; Jiménez-Yuste V; d'Oiron R; Benchikh El Fegoun S; Kessler CM
Haemophilia; 2019 Nov; 25(6):969-978. PubMed ID: 31517435
[TBL] [Abstract][Full Text] [Related]
7. Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B.
Orstavik KH; Scheibel E; Ingerslev J; Schwartz M
Thromb Haemost; 2000 Mar; 83(3):433-7. PubMed ID: 10744150
[TBL] [Abstract][Full Text] [Related]
8. Laying the foundations for gene therapy in Italy for patients with haemophilia A: A Delphi consensus study.
Castaman G; Carulli C; De Cristofaro R; Follino M; Lupi A; Mancuso ME; Mansueto MF; Molinari AC; Pasquetti P; Santoro C; Santoro RC; Siragusa S; Solimeno LP; Tripodi A; Zanon E; Minno GD
Haemophilia; 2023 Mar; 29(2):435-444. PubMed ID: 36469855
[TBL] [Abstract][Full Text] [Related]
9. Definitions for haemophilia prophylaxis and its outcomes: the Canadian consensus study.
Ota S; Mclimont M; Carcao MD; Blanchette VS; Graham N; Paradis E; Feldman BM
Haemophilia; 2007 Jan; 13(1):12-20. PubMed ID: 17212719
[TBL] [Abstract][Full Text] [Related]
10. Personalized prophylaxis.
Collins PW
Haemophilia; 2012 Jul; 18 Suppl 4():131-5. PubMed ID: 22726096
[TBL] [Abstract][Full Text] [Related]
11. Defining severity of hemophilia: more than factor levels.
Pavlova A; Oldenburg J
Semin Thromb Hemost; 2013 Oct; 39(7):702-10. PubMed ID: 24026911
[TBL] [Abstract][Full Text] [Related]
12. Consensus statements on vaccination in patients with haemophilia-Results from the Italian haemophilia and vaccinations (HEVA) project.
Santagostino E; Riva A; Cesaro S; Esposito S; Matino D; Mazzucchelli RI; Molinari AC; Mura R; Notarangelo LD; Tagliaferri A; Di Minno G; Clerici M;
Haemophilia; 2019 Jul; 25(4):656-667. PubMed ID: 30990961
[TBL] [Abstract][Full Text] [Related]
13. Synovitis and joint health in patients with haemophilia: Statements from a European e-Delphi consensus study.
Mancuso ME; Holstein K; O'Donnell JS; Lobet S; Klamroth R;
Haemophilia; 2023 Mar; 29(2):619-628. PubMed ID: 36622258
[TBL] [Abstract][Full Text] [Related]
14. When is enough…enough? Developing consensus of definition of failure of immune tolerance induction in patients with haemophilia and inhibitors.
Barnes C; Brown SA; Curtin J; Dunkley S
Haemophilia; 2014 Jul; 20(4):e275-9. PubMed ID: 24948406
[TBL] [Abstract][Full Text] [Related]
15. Management of cardiovascular disease in aging persons with haemophilia.
Schutgens REG; Voskuil M; Mauser-Bunschoten EP
Hamostaseologie; 2017 Aug; 37(3):196-201. PubMed ID: 27966004
[TBL] [Abstract][Full Text] [Related]
16. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
[TBL] [Abstract][Full Text] [Related]
17. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens.
Berntorp E
Haemophilia; 2009 Nov; 15(6):1219-27. PubMed ID: 19659939
[TBL] [Abstract][Full Text] [Related]
18. [Revision consensus hemophilia: treatment and responsibility. Nederlandse Vereniging van Hemophilia Patients].
Briët E; Mauser-Bunschoten EP
Ned Tijdschr Geneeskd; 1997 Dec; 141(52):2566-71. PubMed ID: 9555158
[TBL] [Abstract][Full Text] [Related]
19. [Prevention of joint damage in hemophilic children with early prophylaxis].
Kreuz W; Escuriola Ettingshausen C; Funk M; Pons S; Schmidt H; Kornhuber B
Orthopade; 1999 Apr; 28(4):341-6. PubMed ID: 10335528
[TBL] [Abstract][Full Text] [Related]
20. Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports.
Wang M; Álvarez-Román MT; Chowdary P; Quon DV; Schafer K
Blood Coagul Fibrinolysis; 2016 Oct; 27(7):737-744. PubMed ID: 27116081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
